Healthpeak Properties (DOC) reported third-quarter results on November 3, 2026 that missed on per-share earnings, beat on revenue and raised full-year guidance, and the stock rose 0.9% to $19.66. The balance of evidence for the next two to six weeks is even, with low conviction. The weekly uptrend is intact, but the shares still sit below their 50-day average and short of a breakout that would make the math worth the risk.
Why it matters
The headline number was a miss: Investing.com reports earnings of $0.02 per share against a consensus of $0.05, while revenue of $813.69 million topped the $747.32 million estimate. The company's own filing tells a different story. In its SEC 8-K, DOC put FFO as Adjusted at $0.44 per share, raised its 2026 earnings guidance, and said it had completed $1.75 billion of senior housing acquisitions through its Janus Living subsidiary, which grew revenue 78% from a year earlier. For a REIT, FFO and guidance carry more weight than GAAP earnings, which helps explain why the miss did not hurt.
The reaction suggests the bad news was either expected or beside the point. The stock gained 0.9% on the day and 3.4% over five days, while the S&P 500 (SPY) fell 2.0% over the same five days. The market did not lift DOC; if anything it was a headwind. No sector ETF comparison is available, so the sector's share of the move cannot be measured, and the gain looks like the stock's own. Part of it is a rebound: on October 5, Nasdaq noted the shares had entered oversold territory. The RSI is now about 60, and the price is 1.6% below the September 30 closing peak of $19.97.
The argument over DOC is only thinly documented in the news feed. The constructive case is laid out in a Seeking Alpha piece headlined around high yield, a strong balance sheet and upside potential. The sector's swing factor is interest rates, the question behind an Investing.com analysis of whether REITs suit a bond rally. The skeptical side has no article in the feed, but its evidence is in the numbers: a GAAP earnings miss, a stock still 13.85% below its 52-week high of $22.82, and a lowest analyst price target of $17.00.
Valuation leaves room on paper. Nineteen analysts rate DOC a buy, with a mean price target of $22.39, 12.2% above the current price. Targets range from $17.00 to $29.00, a spread wide enough to show that the analysts do not agree on how fast the senior housing expansion pays off. At a market value of about $13.9 billion, the stock is being priced on whether the acquisitions lift FFO, not on this quarter's GAAP figure.
What the evidence says
The long-term thesis is intact. Price is above its 40-week average, the 200-day average at $19.15 sits just beneath it, and the stock is up 19.7% over six months and 22.3% year to date, against 10.6% for SPY. The stock is in a pullback inside a larger uptrend, not a new one: it remains 13.85% under its 52-week high, trades below its 10-week average, and has not yet retaken the 50-day average at $19.83.
For the next two to six weeks the balance of evidence is even, and conviction is low at 1 of 4. Two things support the stock: the pullback against the weekly uptrend is not yet stretched, and DOC has led the S&P 500 over 50 days by 0.9 percentage points. Against that, there is no alignment between the weekly trend and the shorter-term picture, which is why only one conviction point is earned. Over 200 days the stock still trails SPY by 0.6 points.
The strongest case against a merely even reading is a positive one. The RSI is near 60, the guidance was raised, the stock beat a falling market by a wide margin over five days, and volume was 4.6% above its 20-day average. It does not tip the balance because the price remains under the 50-day average and the 10-week average, and volume only slightly above normal is not the heavy buying that confirms a turn. That gap is why conviction is not higher.
Levels that matter
The structure holds above $19.26, a swing zone, and a close below it would be the first crack. The trend itself ends below $19.15, the 200-day average, with a weekly close below as the test. The two levels are only about a dime apart, so support is a narrow band, and the round $19.00 sits just under it with $18.31 and $18.00 further down.
The breakout level is a daily close above $19.83, the 50-day average, on volume above its 20-day average. From there the first target is $19.97, which is the September peak, and the second is $20.36, with $20.85 and $21.00 above. The breakout would be wrong below $19.13, which is $19.26 less a quarter of the average daily range. Against that stop the math gives 0.2 to 1 at the first target and 0.8 to 1 at the second. That does not reach the 3 to 1 that makes a breakout worth the risk. It would take a target well above the $21.00 round number, or a re-test of support that lowers the cost of entry, to change that.
What would change the picture
A weekly close below $19.15, the 200-day average, would end the uptrend and make the shares a stock in a downtrend rather than a pullback. The non-price fact that would do it is evidence that the senior housing expansion is not paying: a cut to the full-year guidance just raised, or Janus Living's growth slowing sharply from the 78% revenue pace reported. A daily close above $19.83 on above-average volume would be the first sign that buyers are back.
What to watch
- Next earnings: February 1, 2027. The number that matters is FFO as Adjusted per share, against the $0.44 reported for the third quarter, along with any change to full-year guidance.
- Sector events: moves in bond yields, which drive REIT valuations before any company news; the Investing.com piece above frames the question of how REITs behave in a bond rally.
- Valuation: at $19.66 the stock trades 12.2% below the $22.39 mean price target, inside an analyst range of $17.00 to $29.00.